The ADMC_UPenn study. This is a new prospective longitudinal case-control study of AD and MCI. Participants in this study were recruited at the Penn Memory Center, Alzheimer’s Disease Clinical Center, Perelman School of Medicine, University of Pennsylvania, and the Maria de los Santos Health Center.
This release includes:
Bile Acids, Lipids, PDI, and metabolites measured on the p180 platform platform in plasma and serum. A subset of 127 CSF and plasma samples were obtained on the same day from 112 unique participants (51 AD, 18 MCI and 43 CN), and other traditional biomarker data. SeeClinical data on the cohort, and Protocols